Adding trotabresib to chemoradiotherapy did not improve progression-free or overall survival and was associated with more dose reductions and interruptions.
|Articles|December 10, 2013
New Therapies in Development for Multiple Myeloma
Author(s)Joseph R. Mikhael, MD
In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.
Advertisement
Joseph R. Mikhael, MD, of the Mayo Clinic in Arizona, discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development for multiple myeloma, both for treatment-naive and relapsed refractory patients, including the next-generation novel proteasome inhibitors, ixazomib (MLN9708) and oprozomib. Dr. Mikhael also highlights several monoclonal antibodies.
Advertisement
Related to this article
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed quadruplet induction, extended maintenance, and when a community clinician should call a myeloma center.
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
Daniel Y.C. Heng, MD, MPH, FRCPC, discussed final LITESPARK-011 data, toxicity management, and treatment sequencing in advanced renal cell carcinoma.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Neil Mehta, MD, and Laura Kulik, MD, discussed which patients with HCC awaiting liver transplant may benefit from bridging immunotherapy.
Ryosuke Tateishi, MD, PhD, discussed lifestyle interventions, surveillance, and what the US and Japan can share to prevent MASLD-related liver cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Contextualizing MRD Negativity and PFS Across Treatment Regimens in Relapsed/Refractory Multiple Myeloma
2
CELMoDs With CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
3
Anthracycline Chemo May Accelerate Biological Aging in Breast Cancer Survivors
4
Managing Hypoxia, Anemia, and Cardiac Toxicity With Belzutifan Plus Lenvatinib
5